OrbiMed’s Acadia Pharmaceuticals ACAD Stock Holding History

OrbiMed’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.47M	Buy	+137,000	New	+$3.01M	0.06%	112
2024 Q4	–	Sell	-764,600	Closed	-$11.8M	–	119
2024 Q3	$11.8M	Buy	+764,600	New	+$12.8M	0.21%	76
2021 Q1	–	Sell	-265,772	Closed	-$14.2M	–	159
2020 Q4	$14.2M	Buy	265,772 +158,772	+148%	+$7.88M	0.12%	115
2020 Q3	$4.41M	Buy	+107,000	New	+$4.62M	0.06%	129
2020 Q1	–	Sell	-96,143	Closed	-$4.11M	–	144
2019 Q4	$4.11M	Hold	96,143	–	–	0.06%	107
2019 Q3	$3.46M	Sell	96,143 -5,757	-6%	-$175K	0.07%	101
2019 Q2	$2.72M	Buy	+101,900	New	+$2.6M	0.04%	119
2018 Q3	–	Sell	-4,282,400	Closed	-$65.4M	–	151
2018 Q2	$65.4M	Buy	4,282,400 +941,700	+28%	+$16.8M	0.78%	42
2018 Q1	$75.1M	Buy	3,340,700 +2,491,600	+293%	+$69M	0.93%	37
2017 Q4	$25.6M	Buy	+849,100	New	+$27.2M	0.32%	71
2017 Q2	–	Sell	-1,169,000	Closed	-$40.2M	–	139
2017 Q1	$40.2M	Buy	+1,169,000	New	+$41.3M	0.46%	57
2016 Q2	–	Sell	-1,401,600	Closed	-$39.2M	–	138
2016 Q1	$39.2M	Buy	+1,401,600	New	+$30.6M	0.41%	55
2014 Q1	–	Sell	-135,000	Closed	-$3.37M	–	141
2013 Q4	$3.37M	Sell	135,000 -177,000	-57%	-$4.18M	0.05%	106
2013 Q3	$8.57M	Sell	312,000 -981,000	-76%	-$20.5M	0.15%	83
2013 Q2	$23.5M	Buy	+1,293,000	New	+$17.8M	0.5%	42

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OrbiMed's ACAD Position: Q2 2026 in Review

OrbiMed opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 137,000 shares worth $3.47M. The stake represents 0.06% of the portfolio and ranks #112 among its holdings. This is a return to the name: OrbiMed previously reported a position in ACAD as recently as Q3 2024.

OrbiMed first reported a position in ACAD in Q2 2013 and has held it in 15 quarters since. The position peaked at $75.1M in Q1 2018. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

OrbiMed held 137,000 shares of Acadia Pharmaceuticals worth $3.47M as of Q2 2026.
Acadia Pharmaceuticals was a new OrbiMed position in Q2 2026.
Acadia Pharmaceuticals made up 0.06% of OrbiMed's portfolio in Q2 2026, its #112 holding.
OrbiMed first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
OrbiMed's Acadia Pharmaceuticals position peaked at $75.1M in Q1 2018.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.